Table of Contents

• Overview of [14C]ZIPALERTINIB Clinical Research
• Trial Design and Objectives
• Mass Balance Assessment
• Pharmacokinetics Evaluation
• Metabolism and Distribution Studies
• Participant Population and Enrollment
• Study Methodology and Measurements

Overview of [14C]ZIPALERTINIB Clinical Research

The clinical trial investigating [14C]ZIPALERTINIB represents an important Phase 1 study designed to understand how the human body processes this radiolabeled drug compound^[1]. This type of research is fundamental in drug development because it provides detailed information about where a drug goes in the body, how it is broken down, and how it is eliminated^[1]. The use of a radioactive carbon-14 label allows researchers to track the drug with high precision throughout the body, providing data that would be impossible to obtain through other methods^[1].

The study has been completed, meaning all eight enrolled participants have finished their participation and researchers have collected all necessary data^[1]. As an interventional study, participants received the drug as part of the research protocol, allowing scientists to observe and measure specific outcomes related to drug processing^[1]. This completed status indicates that the research team is now analyzing results to understand the drug’s behavior in the human body.

Trial Design and Objectives

The Phase 1 trial investigating [14C]ZIPALERTINIB was specifically designed as a mass balance study, which is a specialized type of pharmacokinetic research^[1]. The primary objective was to assess the mass balance of zipalertinib following administration of a single oral dose of the radiolabeled compound^[1]. Mass balance studies are critical in drug development because they account for all the drug material that enters and leaves the body, ensuring researchers understand the complete fate of the medication.

The study had multiple interconnected objectives that work together to provide a comprehensive picture of drug processing:

• Mass balance assessment: The primary goal was to determine what happens to the entire dose of [14C]ZIPALERTINIB after it enters the body, tracking how much is eliminated through different routes such as urine and feces^[1]
• Radioactivity quantification: Researchers aimed to quantify TRA concentration equivalents (total radioactivity) in both plasma and whole blood, which represents all drug-related material including the parent drug and its breakdown products^[1]
• Pharmacokinetic characterization: The study was designed to characterize the complete PK profile of zipalertinib in plasma and urine, showing how drug concentrations change over time^[1]
• Blood partitioning analysis: An important objective was to determine the percentage of radioactivity associated with cellular components in whole blood over time, expressed as the whole blood:plasma partitioning ratio^[1]

Mass Balance Assessment

The mass balance assessment represents the cornerstone of this clinical trial, providing crucial information about drug accountability in the body^[1]. In a mass balance study, researchers track the administered dose from the moment it enters the body until it is completely eliminated. The use of the carbon-14 radioactive label in [14C]ZIPALERTINIB makes this tracking highly accurate because the radioactive signal can be detected in all biological samples, including blood, urine, and feces.

Following the single oral dose administration, researchers collected samples over an extended period to capture the complete elimination profile^[1]. The mass balance calculation involves measuring the total amount of radioactivity recovered in excreta (urine and feces) and comparing it to the administered dose. A complete mass balance study typically aims to recover at least 90% of the administered dose to ensure that researchers understand where the drug goes in the body.

This type of assessment is particularly important for understanding whether a drug is primarily eliminated through the kidneys (renal elimination) or through the liver and bile into feces (hepatic elimination). This information has significant implications for how the drug might be used in patients with kidney or liver problems.

Pharmacokinetics Evaluation

The pharmacokinetic evaluation in this trial involved comprehensive characterization of how [14C]ZIPALERTINIB moves through the body over time^[1]. Pharmacokinetics encompasses four major processes: absorption (how the drug enters the bloodstream), distribution (how it spreads to different tissues), metabolism (how it is chemically changed), and elimination (how it leaves the body). Together, these processes are often abbreviated as ADME.

The study characterized the PK profile of zipalertinib in both plasma and urine^[1]. Plasma measurements show how drug concentrations change in the bloodstream over time, revealing important parameters such as:

• Maximum concentration (Cmax): The highest drug level reached in the blood after dosing
• Time to maximum concentration (Tmax): How long it takes to reach the highest blood level
• Area under the curve (AUC): A measure of total drug exposure over time
• Half-life: The time it takes for drug concentration to decrease by half
• Clearance: How efficiently the body removes the drug

Urine measurements provide complementary information about renal elimination, showing how much drug is removed through the kidneys^[1]. By measuring drug concentrations in urine at multiple time points, researchers can calculate the amount and rate of urinary excretion, which is critical for understanding the drug’s elimination pathways.

Metabolism and Distribution Studies

Understanding drug metabolism is a critical objective of the [14C]ZIPALERTINIB trial^[1]. Metabolism refers to the chemical changes that occur when the body processes a drug, typically converting it into more water-soluble compounds that can be more easily eliminated. These breakdown products are called metabolites, and they may be active (having their own effects) or inactive.

The study aimed to quantify TRA concentration equivalents in plasma and whole blood^[1]. Total radioactivity measurements capture not just the parent drug (zipalertinib itself) but also all metabolites that retain the carbon-14 label. By comparing total radioactivity to parent drug concentrations, researchers can determine how extensively the drug is metabolized and identify major metabolic pathways.

An important aspect of the metabolism and distribution assessment involves determining the whole blood:plasma partitioning ratio^[1]. This measurement reveals how the drug distributes between red blood cells and the liquid portion of blood (plasma). Some drugs bind extensively to red blood cells, while others remain primarily in plasma. This ratio has several important implications:

• It affects the interpretation of plasma concentration measurements
• It influences how the drug is distributed to tissues throughout the body
• It may impact drug interactions and efficacy
• It helps researchers understand if blood cells serve as a reservoir for the drug

By measuring radioactivity in both whole blood and plasma over time, researchers can calculate this partitioning ratio and understand how it changes as the drug is eliminated from the body^[1].

Participant Population and Enrollment

The [14C]ZIPALERTINIB trial enrolled eight healthy adult male subjects^[1]. The selection of healthy volunteers rather than patients is typical for Phase 1 mass balance studies. This approach allows researchers to study the drug’s basic pharmacokinetic properties without the confounding effects of disease, other medications, or altered organ function that might be present in patient populations.

The small enrollment number of eight participants is appropriate for this type of study^[1]. Mass balance studies typically use small sample sizes because:

• The measurements are highly precise due to the radioactive tracer
• Pharmacokinetic parameters tend to be consistent among healthy volunteers
• The primary goal is to understand drug behavior rather than demonstrate efficacy
• Regulatory guidelines generally accept small sample sizes for these studies
• Exposure to radioactive materials is minimized by limiting participant numbers

The restriction to male subjects is also common in early Phase 1 studies to avoid potential risks to women of childbearing potential and to reduce variability in pharmacokinetic parameters that might be influenced by hormonal differences. Later phase trials typically include more diverse populations to ensure the drug works safely across different demographic groups.

Study Methodology and Measurements

The methodology employed in this [14C]ZIPALERTINIB trial involved administering a single oral dose of the radiolabeled drug to participants^[1]. The single-dose design is standard for mass balance studies because it allows researchers to track the complete fate of a known quantity of drug from administration through complete elimination. Multiple dosing would complicate the analysis by introducing drug accumulation.

The oral administration route reflects how the drug would likely be given to patients in clinical practice^[1]. Oral dosing introduces the drug through the digestive system, where it must be absorbed before entering the bloodstream. This route provides information about bioavailability (the fraction of the dose that reaches systemic circulation) and first-pass metabolism (drug breakdown that occurs before reaching general circulation).

The study involved collecting multiple types of biological samples:

• Plasma samples: Collected at multiple time points to measure drug and metabolite concentrations in the liquid portion of blood^[1]
• Whole blood samples: Taken to assess total radioactivity and calculate blood cell partitioning^[1]
• Urine samples: Collected over extended periods to quantify renal elimination and characterize urinary pharmacokinetics^[1]
• Fecal samples: While not explicitly mentioned in the objectives, mass balance studies typically collect feces to account for hepatobiliary elimination

The measurements performed on these samples included both radioactivity detection (to track total drug-related material) and specific drug quantification (to measure unchanged zipalertinib)^[1]. Advanced analytical techniques such as liquid scintillation counting detect radioactivity, while methods like liquid chromatography-mass spectrometry measure specific drug concentrations. Together, these complementary approaches provide a complete picture of drug disposition in the human body.